Core Viewpoint - The Jiangsu Provincial Human Resources and Social Security Department has announced the list of new Jiangsu Provincial Postdoctoral Innovation Practice Bases for 2025, with three companies from Jiangning High-tech Zone successfully approved [1] Group 1: Company Achievements - Nanjing Bosh Medical Technology Co., Ltd., Nanjing Ningdan New Drug Technology Co., Ltd., and Nanjing Electric Research Power Automation Co., Ltd. are the three companies that received approval [1] - The approval of these postdoctoral innovation practice bases is a significant recognition of the research and innovation capabilities, talent levels, and technology transfer potential of the applying units [1] Group 2: Industry Implications - The Jiangsu Provincial Postdoctoral Innovation Practice Base aims to promote deep integration of industry, academia, and research, accelerate the transformation of scientific and technological achievements, and cultivate a group of innovative and internationally competitive young scientific and technological talents [1] - Jiangning High-tech Zone will continue to support companies in building high-level R&D platforms, deepening the integration of industry and academia, and accelerating the transformation of achievements to provide strong talent support and innovation momentum for the high-quality economic development of the park [1]

Core Viewpoint - The company has entered into a strategic cooperation memorandum with Mingzhi Medical Technology (Shanghai) Co., Ltd. to integrate core resources using artificial intelligence technology, focusing on real-world research in oncology and innovation in traditional Chinese medicine [1][2] Group 1: Strategic Cooperation - The memorandum aims to promote deep integration and industrial upgrading of "medical + technology + scenarios" [1] - The collaboration will leverage Mingzhi Medical's technological and resource advantages to support the company's transition from traditional property and asset management to a digital AI healthcare service enterprise [1] - Specific cooperation directions include building a digital marketing management system for pharmaceutical companies and a collaborative platform for digital clinical trials [1] Group 2: Business Diversification - The company operates two reportable segments: property management and property development and investment, with operations in China, the United States, and the United Kingdom [2] - The strategic cooperation is expected to enhance the company's financial performance and profitability, aligning with the overall interests of the company and its shareholders [2] - The company is actively seeking business diversification to broaden its revenue sources and improve shareholder returns [2]

每经讯，爱舍伦1月26日发布公告称，为强化海外市场战略布局，公司拟使用自有资金和自筹资金由香 港子公司EXCELLENT MEDICAL TECHNOLOGY CO., LIMITED向摩洛哥孙公司增加1,500万欧元投资 额（即总投资额不超过2,000万欧元），加快摩洛哥孙公司创新医疗的生产基地建设。本次增资拟主要 用于和当地公司CRBC TANGER LIMITED（中国路桥下属公司，施工总承包人）、Lecons Group SARL （施工方）签署建筑工程施工合同，由其承建爱舍伦摩洛哥子公司位于丹吉尔科技城工厂厂房建设的第 一期工程项目；合同总金额为1.5175亿摩洛哥迪拉姆（约1410万欧元）。公司董事会授权管理层办理与 本次对外投资相关的具体事项，包括但不限于进行相关磋商、签订相关法律文件、向有关机构办理审批 备案等手续。 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 ...

Group 1: Amazon's Healthcare Initiative - Amazon's One Medical has launched an AI health assistant named Health AI, providing personalized guidance based on individual patient histories, available 24/7 [1] - The AI tool is integrated with Amazon's existing healthcare services, enhancing the overall medical ecosystem and creating a seamless online-offline experience for users [1] - One Medical operates over 200 clinics in 26 major U.S. cities and offers employee benefits services to 16,000 companies [1] Group 2: Industry Trends in AI Healthcare - Major tech companies are accelerating their investments in the healthcare sector, with Alibaba's Ant Financial app reaching over 30 million monthly active users [2] - OpenAI has launched its first AI healthcare product, ChatGPT Health, to provide health and wellness services [2] - The global AI healthcare market is projected to grow from approximately $26.65 billion in 2024 to about $505.59 billion by 2033, with a compound annual growth rate of 38.8% [2] Group 3: Company Developments in AI Healthcare - RunDa Medical reported a 40.73% year-on-year revenue increase in its medical information business, achieving 0.94 billion yuan in the first half of 2025 [3] - The company is focusing on AI strategies across B, C, and G sectors, creating a closed-loop ecosystem for pre-diagnosis, diagnosis, and post-diagnosis [3] - HuaRen Health is actively developing AI applications in healthcare, including AI systems for sales scenarios and employee training, to explore the potential of intelligent technology in medical services [3]

Core Insights - Breyer Capital predicts that the intersection of AI and healthcare/life sciences will be the most lucrative investment opportunity in the next ten to twenty years [3] - The article emphasizes the transformative impact of AI on healthcare, highlighting five key insights, including the emergence of weight loss drugs, in vivo therapies, and anti-aging technologies driven by technology [5] Group 1: Market Trends - The healthcare technology sector is expected to undergo significant consolidation, with 2026 being a pivotal year for mergers and acquisitions in the private equity market [6] - In 2025, healthcare technology investments grew by 35% year-on-year to $14.2 billion, but over 40% of this capital was concentrated in a few mega-rounds, indicating a trend of capital concentration rather than broad recovery [7] - M&A activity surged by over 60%, while the IPO window remained largely closed [7] Group 2: AI in Clinical Applications - Clinical AI is redefining medical paradigms by shifting diagnostics from subjective, discrete judgments to objective, continuous quantitative monitoring [12] - AI is extracting new quantifiable signals from various data sources, pushing healthcare from discrete events to continuous physiological states [15] - The ACCESS payment model, set to launch in 2026, will incentivize continuous monitoring capabilities achieved through clinical AI [54] Group 3: AI in Drug Development - 2026 is anticipated to be a landmark year for AI in drug development, marking the emergence of new business models [17] - Traditional binary models of either developing drug assets or selling AI tools are breaking down, leading to more diverse transaction forms [17] - A core challenge remains in determining the value return for AI contributions in successful drug launches, especially given the high costs associated with drug development [55][56] Group 4: Weight Loss Drug Market - The GLP-1 drug market is evolving from a dual-monopoly of injectables to a competitive landscape with multiple forms and pathways [57] - The market is shifting from a supply-constrained state to one driven by efficacy, convenience, and price [60] - By 2035, the market size is projected to approach $180 billion, necessitating precise matching of therapies to patient types [61][62] Group 5: In Vivo Therapies - In vivo delivery is disrupting traditional ex vivo cell and gene therapies, allowing patients to become their own "production facilities" for drugs [65] - Recent significant transactions indicate that in vivo therapies are maturing, with the potential for scalable manufacturing [68] Group 6: Anti-Aging Research - The field of aging biology is gaining prominence in biomedicine, with major pharmaceutical companies investing heavily in this area [32][69] - Regulatory frameworks have yet to catch up with scientific advancements, particularly regarding the classification of aging as a disease [69] Group 7: Clinical Trials Transformation - Clinical trials are expected to undergo substantial changes in 2026, with a shift in how animal models and trial designs are approached [34] - The FDA's guidance on Bayesian statistical methods could lead to smaller, more efficient trials [70] Group 8: Preventive Healthcare - The trend towards consumer-centered preventive healthcare is accelerating, driven by demographic changes and rising user expectations [73] - Companies in preventive health must transition from providing mere information to building clinical infrastructures to capture long-term health value [74] Group 9: AI Development in Healthcare - The role of healthcare professionals is shifting from end-users to developers of software, with the emergence of Vibe Coding lowering barriers to software creation [75][78] - A wave of micro-applications is expected to arise, focusing on specific pain points in healthcare [78] Group 10: Autonomous Systems in Healthcare - Autonomous systems are moving from concept to real deployment in healthcare services and life sciences research [80] - The introduction of AI systems for automatic prescription renewals marks a significant shift towards decentralization in healthcare [81]

记者从华中科技大学获悉，1月25日，华中科技大学脑机接口研究院在梧桐语问学中心宣告成立。 脑机接口研究院挂靠该校科学技术发展院，由同济医学院附属同济医院牵头，联合附属协和医院、机械学院、人工智能与自动化学 院等31个校内单位共同建设，唐洲平为研究院院长。 研究院院长唐洲平表示，研究院将致力于打通"从大脑到产品"的全链条，做临床价值的坚定守护者、开放合作的积极践行者和负责 任创新的坚定倡导者。 据介绍，华中科技大学脑机接口研究院将按照"科学—技术—工程—临床—治理"的全链条进行布局，下设基础研究、技术研发、系 统工程、临床转化四大中心，并以伦理与标准支撑平台为保障，目标是建设成为集前沿基础研究、核心技术攻关、系统工程实现、临床 转化应用与产业孵化于一体的世界级创新平台，为服务健康中国战略、实现高水平科技自立自强贡献力量。 脑机接口是大脑与外部设备直接连接的技术，分侵入式、非侵入式、半侵入式三种路线，医疗康复是主导应用。在武汉，脑机接口 技术正快速进入临床转化与产业发展阶段。截至2026年1月，武汉脑机接口领域在临床手术、技术研发和政策支持方面取得多项突破性进 展，同济医院和协和医院成功实施多例国产芯片植入手术， ...

为最大化释放APEC会议溢出效应，推动"办会"与"兴城"同频共振，尚海龙提出七大针对性建议，包 括：打造"APEC数字治理（中国南山）实验室"；推出"APEC绿色供应链南山导则"；打造"双城"模式服 务盛会，深化"深港合作"；设立"APEC主题产业园"，固化长期合作平台；对标APEC标准，实施"城市 国际化提升计划"；打造沉浸式参访路线，讲好"南山故事"；服务国家战略，推动"制度型开放"压力测 试 尚海龙表示，APEC落地深圳将为南山带来三重发展升级契机：首先是成为向亚太乃至全球输出数字经 济、绿色低碳等领域"深圳标准""南山方案"的国际话语权放大器；其次，将吸引亚太创新资源集聚，推 动本地"20+8"产业集群与国际创新链深度融合的产业升级聚宝盆；第三，可以以国际标准倒逼城市基 建、服务、生态提质的城市能级催化剂。 1月26日，南山区政协六届七次会议开幕，大会现场，南山区政协常委、商汤医疗联合创始人、香港高 才资本创始人尚海龙围绕《把握APEC历史机遇，打造南山国际创新枢纽》作发言。他表示，APEC在 深圳举行对南山而言不仅是荣耀，更是站在更高起点，向世界展示"中国硅谷"创新活力、提升城市能 级、加速国际化进 ...

Group 1 - The company, Yidu Tech (02158.HK), announced a share buyback on January 26, spending HKD 758,000 to repurchase 126,000 shares [1]

Group 1 - The National Development and Reform Commission will hold a press conference on January 26 to discuss the business work and operational situation for 2025 [1] - The National Health Commission will hold a press conference on January 26 to introduce the promotion of the Sanming medical reform experience and the development of traditional Chinese medicine [2] - The 19th Asian Financial Forum will take place from January 26 to 27, focusing on how high-growth industries impact the global economy, including sectors like fintech, healthcare technology, new energy, artificial intelligence, and green technology [3] Group 2 - On January 26, a total of 8 companies will have their restricted shares unlocked, with a total of 164 million shares and a market value of 4.449 billion yuan based on the latest closing price [4] - Among the companies, Yifang Bio-U, Ophtai, and Yuntian Lifei-U have the highest unlock volumes, with 161 million shares, 952,100 shares, and 776,700 shares respectively [4] - Yifang Bio-U, Rongchang Bio, and Yuntian Lifei-U have the highest unlock market values, at 4.251 billion yuan, 78.4656 million yuan, and 67.5979 million yuan respectively [4] Group 3 - Two companies disclosed stock repurchase progress on January 26, with one company announcing a new repurchase plan exceeding 100 million yuan [5] - Zhongchong Co. plans to repurchase up to 200 million yuan worth of shares, while Kaifa Electric has completed a repurchase amounting to 31.7282 million yuan [5] Group 4 - One company announced a private placement on January 26, with one plan being halted [6] Group 5 - One A-share will undergo stock rights registration on January 26, with Xiyi Co. declaring the highest dividend of 1.10 yuan per 10 shares [7] Group 6 - Economic data including the Dallas Fed Business Activity Index for January and Germany's IFO Business Climate Index will be released [8]

Core Viewpoint - The integration of AI in healthcare is rapidly advancing, with significant potential benefits in diagnostics and treatment, but it also raises concerns about accuracy, practicality, and the impact on medical professionals' skills [1][5][9]. Group 1: AI Applications in Healthcare - AI is being utilized in various medical applications such as diagnostic assistance, medical record writing, and pre-consultation, with ongoing developments supported by government initiatives [1][2]. - The average accuracy of prenatal diagnosis for congenital defects is only 30%-60%, indicating a significant opportunity for AI to improve outcomes in cases like congenital diaphragmatic hernia [2][7]. - AI has shown high efficiency in areas like image recognition, pathology interpretation, and chronic disease management, which can reduce diagnostic time and human error [3][9]. Group 2: Concerns and Challenges - There are concerns that reliance on AI may lead to a decline in the diagnostic skills of younger doctors, as they may become overly dependent on AI tools [5][6]. - The accuracy of AI is not guaranteed, and it is essential for doctors to maintain their diagnostic authority and critical thinking when using AI [5][6]. - Challenges include the lack of a mature reimbursement system for AI-assisted diagnostics and the need for funding and support for AI development in healthcare [8][9]. Group 3: Regulatory and Development Recommendations - Recommendations include establishing a clinical access and evaluation system for AI medical products, ensuring safety and efficacy in real-world applications [9][10]. - It is suggested that pilot programs be initiated in community health centers and secondary hospitals to demonstrate the effectiveness of AI applications in healthcare [10]. - The government is encouraged to integrate AI into health city and digital governance initiatives to promote collaborative development among industry, hospitals, research, and regulation [10].